162 related articles for article (PubMed ID: 23328160)
1. Prognostic factors including Ki-67 and p53 in Bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer: a prospective study.
Oderda M; Ricceri F; Pisano F; Fiorito C; Gurioli A; Casetta G; Zitella A; Pacchioni D; Gontero P
Urol Int; 2013; 90(2):184-90. PubMed ID: 23328160
[TBL] [Abstract][Full Text] [Related]
2. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
3. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
5. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
[TBL] [Abstract][Full Text] [Related]
7. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.
Alvarez-Múgica M; Fernández-Gómez JM; Cebrian V; Fresno F; Escaf S; Sánchez-Carbayo M
Eur Urol; 2013 Feb; 63(2):364-70. PubMed ID: 22682992
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
[TBL] [Abstract][Full Text] [Related]
10. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy.
Ajili F; Manai M; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2012 Oct; 36(5):320-4. PubMed ID: 23025650
[TBL] [Abstract][Full Text] [Related]
11. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
12. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
[TBL] [Abstract][Full Text] [Related]
13. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer.
Matsumoto K; Kikuchi E; Shirakawa H; Hayakawa N; Tanaka N; Ninomiya A; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Dec; 110(11 Pt B):E508-13. PubMed ID: 22574662
[TBL] [Abstract][Full Text] [Related]
14. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
Boorjian SA; Zhu F; Herr HW
BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
van Rhijn BW; Liu L; Vis AN; Bostrom PJ; Zuiverloon TC; Fleshner NE; van der Aa MN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Bapat B; van der Kwast TH; Zlotta AR
BJU Int; 2012 Oct; 110(8):1169-76. PubMed ID: 22448597
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer.
Shirakawa H; Kikuchi E; Tanaka N; Matsumoto K; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Sep; 110(6 Pt B):E216-21. PubMed ID: 22313616
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
Ovesen H; Horn T; Steven K
J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
[TBL] [Abstract][Full Text] [Related]
20. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
